Q-omics provides the consensus-scored PLXNB2 profile across patient tissues and cancer cell-line models. PLXNB2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, PLXNB2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, PLXNB2 RNA expression shows 19,402 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, THCA, and ACC as cancer lineages where PLXNB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLXNB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLXNB2 survival associations across molecular data types. PLXNB2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (15) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLXNB2 RNA expression–survival associations across cancer types. High PLXNB2 expression shows unfavorable associations in LGG, MESO, OV and PAAD, but favorable associations in UCEC and ESCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for PLXNB2 RNA expression.
This table summarizes PLXNB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PLXNB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLXNB2 shows lower tumor expression in KICH and higher tumor expression in THCA, HNSC, LIHC, BLCA and STAD. The THCA box plot shows higher PLXNB2 RNA expression in tumor versus normal tissue (log2 FC = +0.818, t-test p < 0.001).
This table shows molecular features associated with PLXNB2 in patient tissues and cancer cell lines. In patient samples, PLXNB2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLXNB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
